Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.
de Haas SL, de Visser SJ, van der Post JP, Schoemaker RC, van Dyck K, Murphy MG, de Smet M, Vessey LK, Ramakrishnan R, Xue L, Cohen AF, van Gerven JM. de Haas SL, et al. Among authors: van gerven jm, van der post jp, van dyck k. J Psychopharmacol. 2008 Jan;22(1):24-32. doi: 10.1177/0269881107082108. J Psychopharmacol. 2008. PMID: 18187530
The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol.
Zoethout RW, Iannone R, Bloem BR, Palcza J, Murphy G, Chodakewitz J, Buntinx A, Gottesdiener K, Marsilio S, Rosen L, van Dyck K, Louis ED, Cohen AF, Schoemaker RC, Tokita S, Sato N, Koblan KS, Hargreaves RH, Renger J, van Gerven JM. Zoethout RW, et al. Among authors: van gerven jm, van dyck k. J Psychopharmacol. 2012 Feb;26(2):292-302. doi: 10.1177/0269881111398685. Epub 2011 Feb 18. J Psychopharmacol. 2012. PMID: 21335358 Clinical Trial.
Placebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state.
te Beek ET, Tatosian D, Majumdar A, Selverian D, Klaassen ES, Petty KJ, Gargano C, van Dyck K, McCrea J, Murphy G, van Gerven JM. te Beek ET, et al. Among authors: van gerven jm, van dyck k. J Clin Pharmacol. 2013 Aug;53(8):846-56. doi: 10.1002/jcph.120. Epub 2013 Jun 18. J Clin Pharmacol. 2013. PMID: 23775877 Clinical Trial.
Sputum RNA signature in allergic asthmatics following allergen bronchoprovocation test.
Zuiker RG, Tribouley C, Diamant Z, Boot JD, Cohen AF, Van Dyck K, De Lepeleire I, Rivas VM, Malkov VA, Burggraaf J, Ruddy MK. Zuiker RG, et al. Among authors: van dyck k. Eur Clin Respir J. 2016 Jul 13;3:31324. doi: 10.3402/ecrj.v3.31324. eCollection 2016. Eur Clin Respir J. 2016. PMID: 27421833 Free PMC article.
Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
Nygren P, Hande K, Petty KJ, Fedgchin M, van Dyck K, Majumdar A, Panebianco D, de Smet M, Ahmed T, Murphy MG, Gottesdiener KM, Cocquyt V, van Belle S. Nygren P, et al. Among authors: van belle s, van dyck k. Cancer Chemother Pharmacol. 2005 Jun;55(6):609-16. doi: 10.1007/s00280-004-0946-3. Epub 2005 Feb 19. Cancer Chemother Pharmacol. 2005. PMID: 15723220 Clinical Trial.
Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Krishna R, Bergman AJ, Jin B, Fallon M, Cote J, Van Hoydonck P, Laethem T, Gendrano IN 3rd, Van Dyck K, Hilliard D, Laterza O, Snyder K, Chavez-Eng C, Lutz R, Chen J, Bloomfield DM, De Smet M, Van Bortel LM, Gutierrez M, Al-Huniti N, Dykstra K, Gottesdiener KM, Wagner JA. Krishna R, et al. Among authors: van hoydonck p, van dyck k, van bortel lm. Clin Pharmacol Ther. 2008 Dec;84(6):679-83. doi: 10.1038/clpt.2008.109. Epub 2008 Jun 25. Clin Pharmacol Ther. 2008. PMID: 18580870 Clinical Trial. No abstract available.
Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.
Li CC, Vermeersch S, Denney WS, Kennedy WP, Palcza J, Gipson A, Han TH, Blanchard R, De Lepeleire I, Depré M, Murphy MG, Van Dyck K, de Hoon JN. Li CC, et al. Among authors: van dyck k. Br J Clin Pharmacol. 2015 May;79(5):831-7. doi: 10.1111/bcp.12547. Br J Clin Pharmacol. 2015. PMID: 25377933 Free PMC article. Clinical Trial.
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA. Herman GA, et al. Among authors: van dyck k. J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. doi: 10.1210/jc.2006-1009. Epub 2006 Aug 15. J Clin Endocrinol Metab. 2006. PMID: 16912128 Clinical Trial.
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA. Herman GA, et al. Among authors: van dyck k. Clin Pharmacol Ther. 2005 Dec;78(6):675-88. doi: 10.1016/j.clpt.2005.09.002. Clin Pharmacol Ther. 2005. PMID: 16338283 Clinical Trial.
46 results